Skip to menu Skip to content Skip to footer
Professor Brian Gabrielli
Professor

Brian Gabrielli

Email: 

Overview

Background

Professor Gabrielli completed his undergraduate education at James Cook University in Townsville and PhD at La Trobe University in Melbourne. After two postdoctoral positions in the USA in the emerging field of cell cycle regulation, he was recruited to establish his own independent research at the Queensland Institute of Medical Research, and then recruited to the Diamantina Institute in 2002, and Mater Research Institute in 2016. He is head of the Smiling for Smiddy Cell Cycle Group.

Research Interests

Mechanisms that regulate cell division, particularly progression into mitosis. These mechanisms are often mutated in cancers and are likely to be major contributors to cancer development. Identifying the genetic mutations that disrupt normal progression and particularly mechanisms, known as checkpoints, provides diagnostic and prognostic opportunities. It also provides potential new targets for chemotherapeutics as drugs targeting defective checkpoints have tumour selective cytotoxic potential.

Research Projects

  • Identifying the molecular basis for defective checkpoints in melanoma.
  • Targeting defective cell cycle responses to ultraviolet radiation, replication stress and TopoII inhibitors in melanoma, and investigating whether the same defects in other cancer types respond to similar targeting.
  • Investigating means of identify very early changes in moles that drive progression to melanoma
  • Targeting Aurora kinases in HPV-driven cancers

Availability

Professor Brian Gabrielli is:
Available for supervision
Media expert

Qualifications

  • Bachelor (Honours) of Science (Advanced), James Cook University
  • Doctor of Philosophy, La Trobe University

Research interests

  • Ultraviolet radiaiton and its contribution to melanoma

  • Targeting defective cell cycle checkpoints in cancers, particularly melanoma

  • Functional genomics; using high throughout screening combined with increased or decreased gene dosage to identify novel regulatory mechanisms and drug targets

  • Mechanism of action studies for novel anti-caner therapeutics

Works

Search Professor Brian Gabrielli’s works on UQ eSpace

160 works between 1984 and 2024

1 - 20 of 160 works

2024

Journal Article

Aurora B inhibitors promote RB hypophosphorylation and senescence independent of p53-dependent CDK2/4 inhibition

Vora, Shivam, Andrew, Ariel, Kumar, Ramyashree Prasanna, Nazareth, Deborah, Bonfim-Melo, Alexis, Lim, Yoon, Ong, Xin Yee, Fernando, Madushan, He, Yaowu, Hooper, John D., McMillan, Nigel AJ, Urosevic, Jelena, Travers, Jon, Saeh, Jamal, Kumar, Sharad, Jones, Mathew JK and Gabrielli, Brian (2024). Aurora B inhibitors promote RB hypophosphorylation and senescence independent of p53-dependent CDK2/4 inhibition. Cell Death & Disease, 15 (11) 810, 810. doi: 10.1038/s41419-024-07204-5

Aurora B inhibitors promote RB hypophosphorylation and senescence independent of p53-dependent CDK2/4 inhibition

2024

Journal Article

The ATM Ser49Cys variant effects ATM function as a regulator of oncogene-induced senescence

Atkinson, Caroline, McInerney-Leo, Aideen, Proctor, Martina, Lanagan, Catherine, Stevenson, Alexander, Dehkhoda, Farhad, Caole, Mary, Maas, Ellie, Ainger, Stephen, Pritchard, Antonia, Johansson, Peter, Leo, Paul, Hayward, Nicholas, Sturm, Richard, Duncan, Emma and Gabrielli, Brian (2024). The ATM Ser49Cys variant effects ATM function as a regulator of oncogene-induced senescence. International Journal of Molecular Sciences, 25 (3) 1664, 1-12. doi: 10.3390/ijms25031664

The ATM Ser49Cys variant effects ATM function as a regulator of oncogene-induced senescence

2024

Journal Article

Checkpoint kinase 1 inhibitor + low‐dose hydroxyurea efficiently kills BRAF inhibitor‐ and immune checkpoint inhibitor‐resistant melanomas

Zeng, Zhen, Ngo, Hung Long, Proctor, Martina, Rizos, Helen, Dolcetti, Riccardo, Cruz, Jazmina Gonzalez, Wells, James W. and Gabrielli, Brian (2024). Checkpoint kinase 1 inhibitor + low‐dose hydroxyurea efficiently kills BRAF inhibitor‐ and immune checkpoint inhibitor‐resistant melanomas. Pigment Cell and Melanoma Research, 37 (1), 45-50. doi: 10.1111/pcmr.13120

Checkpoint kinase 1 inhibitor + low‐dose hydroxyurea efficiently kills BRAF inhibitor‐ and immune checkpoint inhibitor‐resistant melanomas

2024

Journal Article

Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells

Shah, Esha T., Molloy, Christopher, Gough, Madeline, Kryza, Thomas, Samuel, Selwin G., Tucker, Amos, Bhatia, Maneet, Ferguson, Genevieve, Heyman, Rebecca, Vora, Shivam, Monkman, James, Bolderson, Emma, Kulasinghe, Arutha, He, Yaowu, Gabrielli, Brian, Hooper, John D., Richard, Derek J., O’Byrne, Kenneth J. and Adams, Mark N. (2024). Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells. British Journal of Cancer, 130 (7), 1196-1205. doi: 10.1038/s41416-024-02584-z

Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells

2023

Conference Publication

MITF-mediated changes of tumour architecture, tensile stress and in extracellular matrix (ECM) control intratumour heterogeneity in melanoma

Spoerri, L., Tonnessen-Murray, C. A., Beaumont, K. A., Hill, D. S., Jurek, R. J., Gunasingh, G., Vanwalleghem, G., Daignault, S., Fane, M. E., Schaider, H., Smith, A., Stehbens, S. J., Weninger, W., Scott, E. E., Gabrielli, B. and Haass, N. (2023). MITF-mediated changes of tumour architecture, tensile stress and in extracellular matrix (ECM) control intratumour heterogeneity in melanoma. Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF), Berlin, Germany, 11-14 March 2020. Chichester, West Sussex United Kingdom: Wiley-Blackwell.

MITF-mediated changes of tumour architecture, tensile stress and in extracellular matrix (ECM) control intratumour heterogeneity in melanoma

2022

Journal Article

Repurposing of commercially existing molecular target therapies to boost the clinical efficacy of immune checkpoint blockade

Sinha, Debottam, Moseley, Philip, Lu, Xuehan, Wright, Quentin, Gabrielli, Brian, Frazer, Ian H. and Cruz, Jazmina L. G. (2022). Repurposing of commercially existing molecular target therapies to boost the clinical efficacy of immune checkpoint blockade. Cancers, 14 (24) 6150, 1-26. doi: 10.3390/cancers14246150

Repurposing of commercially existing molecular target therapies to boost the clinical efficacy of immune checkpoint blockade

2021

Journal Article

Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression

Proctor, Martina, Gonzalez Cruz, Jazmina L., Daignault-Mill, Sheena M., Veitch, Margaret, Zeng, Bijun, Ehmann, Anna, Sabdia, Muhammed, Snell, Cameron, Keane, Colm, Dolcetti, Riccardo, Haass, Nikolas K., Wells, James W. and Gabrielli, Brian (2021). Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. Cancers, 13 (15) 3733, 1-19. doi: 10.3390/cancers13153733

Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression

2021

Journal Article

Dysregulated G2 phase checkpoint recovery pathway reduces DNA repair efficiency and increases chromosomal instability in a wide range of tumours

Fernando, Madushan, Duijf, Pascal H. G., Proctor, Martina, Stevenson, Alexander J., Ehmann, Anna, Vora, Shivam, Skalamera, Dubravka, Adams, Mark and Gabrielli, Brian (2021). Dysregulated G2 phase checkpoint recovery pathway reduces DNA repair efficiency and increases chromosomal instability in a wide range of tumours. Oncogenesis, 10 (5) 41, 41. doi: 10.1038/s41389-021-00329-8

Dysregulated G2 phase checkpoint recovery pathway reduces DNA repair efficiency and increases chromosomal instability in a wide range of tumours

2020

Journal Article

Smart drug combinations for cervical cancer: dual targeting of Bcl-2 family of proteins and aurora kinases

Yumol, Jacklyn, Gabrielli, Brian, Tayyar, Yaman, McMillan, Nigel Aj and Idris, Adi (2020). Smart drug combinations for cervical cancer: dual targeting of Bcl-2 family of proteins and aurora kinases. American Journal of Cancer Research, 10 (10), 3406-3414.

Smart drug combinations for cervical cancer: dual targeting of Bcl-2 family of proteins and aurora kinases

2020

Journal Article

Unexpected high levels of BRN2/POU3F2 expression in human dermal melanocytic nevi

Chitsazan, Arash, Lambie, Duncan, Ferguson, Blake, Handoko, Herlina Y., Gabrielli, Brian, Walker, Graeme J. and Boyle, Glen M. (2020). Unexpected high levels of BRN2/POU3F2 expression in human dermal melanocytic nevi. Journal of Investigative Dermatology, 140 (6), 1299-1302.e4. doi: 10.1016/j.jid.2019.12.007

Unexpected high levels of BRN2/POU3F2 expression in human dermal melanocytic nevi

2019

Conference Publication

Inhibition of Aurora B kinase activity triggers senescence that can be bypassed by blocking p53 and RB function, promoting replication stress

Andrews, Ariel, Kumar, Ramyashree Prasanna, Nazareth, Deborah, Ehmann, Anna, Hooper, John, McMillan, Nigel and Gabrielli, Brian (2019). Inhibition of Aurora B kinase activity triggers senescence that can be bypassed by blocking p53 and RB function, promoting replication stress. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA USA, 26-30 October 2019. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/1535-7163.TARG-19-A060

Inhibition of Aurora B kinase activity triggers senescence that can be bypassed by blocking p53 and RB function, promoting replication stress

2019

Journal Article

Melanoma mutations modify melanocyte dynamics in co-culture with keratinocytes or fibroblasts

Škalamera, Dubravka, Stevenson, Alexander J., Ehmann, Anna, Ainger, Stephen A., Lanagan, Catherine, Sturm, Richard A. and Gabrielli, Brian (2019). Melanoma mutations modify melanocyte dynamics in co-culture with keratinocytes or fibroblasts. Journal of Cell Science, 132 (24) jcs234716, jcs234716. doi: 10.1242/jcs.234716

Melanoma mutations modify melanocyte dynamics in co-culture with keratinocytes or fibroblasts

2019

Journal Article

Multiple interaction nodes define the post-replication repair response to UV-induced DNA damage that is defective in melanomas and correlated with UV signature mutation load

Pavey, Sandra, Pinder, Alex, Fernando, Winnie, D'Arcy, Nicholas, Matigian, Nicholas, Skalamera, Dubravka, Lê Cao, Kim-Anh, Loo-Oey, Dorothy, Hill, Michelle M., Stark, Mitchell, Kimlin, Michael, Burgess, Andrew, Cloonan, Nicole, Sturm, Richard A. and Gabrielli, Brian (2019). Multiple interaction nodes define the post-replication repair response to UV-induced DNA damage that is defective in melanomas and correlated with UV signature mutation load. Molecular Oncology, 14 (1) 1878-0261.12601, 22-41. doi: 10.1002/1878-0261.12601

Multiple interaction nodes define the post-replication repair response to UV-induced DNA damage that is defective in melanomas and correlated with UV signature mutation load

2019

Journal Article

Everything in moderation: lessons learned by exploiting moderate replication stress in cancer

Nazareth, Deborah, Jones, Matthew J.K. and Gabrielli, Brian (2019). Everything in moderation: lessons learned by exploiting moderate replication stress in cancer. Cancers, 11 (9) 1320, 1320. doi: 10.3390/cancers11091320

Everything in moderation: lessons learned by exploiting moderate replication stress in cancer

2019

Journal Article

Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine

Oo, Zay Yar, Proctor, Martina, Stevenson, Alexander J., Nazareth, Deborah, Fernando, Madushan, Daignault, Sheena M., Lanagan, Catherine, Walpole, Sebastian, Bonazzi, Vanessa, Škalamera, Dubravka, Snell, Cameron, Haass, Nikolas K., Larsen, Jill E. and Gabrielli, Brian (2019). Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine. Molecular Oncology, 13 (7) 1878-0261.12497, 1503-1518. doi: 10.1002/1878-0261.12497

Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine

2019

Conference Publication

Bortezomib-induced immunogenic cell death enhances immune response in melanoma

Daignault, S. M., Ju, R., Spoerri, L., Stehbens, S. J., Hill, D. S., Gabrielli, B., Dolcetti, R. and Haass, N. K. (2019). Bortezomib-induced immunogenic cell death enhances immune response in melanoma. Society for Investigative Dermatology (SID) Meeting, Chicago, IL United States, 8-11 May 2019. London, United Kingdom: Nature Publishing Group. doi: 10.1016/j.jid.2019.03.907

Bortezomib-induced immunogenic cell death enhances immune response in melanoma

2019

Conference Publication

Subclinical doses and choice of replication stress inducer in combination with CHK1 inhibitors for optimal tumor control and immune responses in vitro and in vivo

Oo, Zay Yar, Proctor, Martina, Stevenson, Alex, Nazareth, Deborah, Larsen, Jill, Haass, Nikolas and Gabrielli, Brian G. (2019). Subclinical doses and choice of replication stress inducer in combination with CHK1 inhibitors for optimal tumor control and immune responses in vitro and in vivo. AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology, Atlanta Ga, Mar 29-Apr 03, 2019. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. doi: 10.1158/1538-7445.AM2019-1236

Subclinical doses and choice of replication stress inducer in combination with CHK1 inhibitors for optimal tumor control and immune responses in vitro and in vivo

2018

Journal Article

Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers

Shaikh, Mushfiq H., Idris, Adi, Johnson, Newell W., Fallaha, Sora, Clarke, Daniel T.W., Martin, David, Morgan, Iain M., Gabrielli, Brian and McMillan, Nigel A. J. (2018). Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers. Oral Oncology, 86, 105-112. doi: 10.1016/j.oraloncology.2018.09.006

Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers

2018

Journal Article

Pathway dysregulation analysis of the nucleotide excision repair mechanisms reveals it is not a common feature of melanomas

D’Arcy, Nicholas, Matigian, Nicholas, Lê Cao, Kim-Anh and Gabrielli, Brian (2018). Pathway dysregulation analysis of the nucleotide excision repair mechanisms reveals it is not a common feature of melanomas. Pigment Cell & Melanoma Research, 32 (2), 336-338. doi: 10.1111/pcmr.12740

Pathway dysregulation analysis of the nucleotide excision repair mechanisms reveals it is not a common feature of melanomas

2018

Journal Article

CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer

Kalimutho, Murugan, Sinha, Debottam, Jeffery, Jessie, Nones, Katia, Srihari, Sriganesh, Fernando, Winnie C., Duijf, Pascal H. G., Vennin, Claire, Raninga, Prahlad, Nanayakkara, Devathri, Mittal, Deepak, Saunus, Jodi M., Lakhani, Sunil R., López, J Alejandro, Spring, Kevin J., Timpson, Paul, Gabrielli, Brian, Waddell, Nicola and Khanna, Kum Kum (2018). CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Molecular Medicine, 10 (9) e8566. doi: 10.15252/emmm.201708566

CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer

Funding

Current funding

  • 2023 - 2026
    Targeting replication stress to improve immune recognition and reduce immunosuppressive in the tumour microenvironment
    Ovarian Cancer Research Foundation Research Grants
    Open grant

Past funding

  • 2021 - 2024
    Enhancing tumour immune detection by targeting replication stress
    Established Investigator
    Open grant
  • 2018 - 2020
    Towards clinical diagnosis of inflammatory skin rashes using minimally-invasive microsampling techniques
    TRI Spore Grants
    Open grant
  • 2018 - 2019
    Preclinical development of combinations with CHK1 inhibitors in melanoma and lung cancer
    Cancer Council Queensland
    Open grant
  • 2016 - 2019
    Aurora A as a novel therapeutic target for HPV-driven cancers (NHMRC Project Grant administered by Griffith University)
    Griffith University
    Open grant
  • 2016
    Epigenetic remodelling driving acquired permanent drug resistance in melanoma cells
    PA Research Foundation
    Open grant
  • 2015 - 2018
    Defining the role of Microphthalmia-associated Transcription Factor (MITF) in melanoma heterogeneity by real-time cell cycle imaging
    NHMRC Project Grant
    Open grant
  • 2015
    Next-generation cell analysis: Automated high-throughput 3D microscope and multimode microplate reader
    NHMRC Equipment Grant
    Open grant
  • 2015 - 2016
    Novel therapeutic targets for HPV-driven cancers (Cancer Council Queensland grant administered by Griffith University
    Griffith University
    Open grant
  • 2015
    Targeting HPV in oropharyngeal cancers
    PA Research Foundation
    Open grant
  • 2014
    Calibration of single channel and liquid handling robots
    UQ Major Equipment and Infrastructure
    Open grant
  • 2014 - 2016
    Identifying the mechanism of the G2 phase UV checkpoint and repair response commonly defective in melanoma
    NHMRC Project Grant
    Open grant
  • 2014
    Purchase of low O2 incubator and Dissociator
    NHMRC Equipment Grant
    Open grant
  • 2013
    Functional characterization of the regulatory architecture of melanoma-associated loci
    NHMRC Project Grant
    Open grant
  • 2013 - 2015
    Functional characterization of the regulatory architecture of melanoma-associated loci (NHMRC Project Grant administered by Garvan Institute)
    Garvan Institute
    Open grant
  • 2012 - 2015
    Functional assessment of new melanoma genomic mutations
    Worldwide Cancer Research
    Open grant
  • 2012 - 2015
    Determining Predictors of Sensitivity to CHK Inhibitors in Metastatic Melanoma (Cancer Australia grant administered by the University of Melbourne)
    University of Melbourne
    Open grant
  • 2012 - 2013
    Defining a response to UV exposure that is defective in melanoma
    Cancer Council Queensland
    Open grant
  • 2012 - 2015
    Synthetic lethality screen targeting a defective checkpoint in melanoma
    NHMRC Project Grant
    Open grant
  • 2012
    Validation of genes potentially involved in early stage melanoma using immunohistochemistry
    Queensland Pharmacy Research Trust
    Open grant
  • 2011
    Laser Scanner for Biomolecular Imaging
    NHMRC Equipment Grant
    Open grant
  • 2011
    Targeting the G2 phase checkpoint in Glioblastoma to improve the efficacy of current therapy
    Brain Foundation
    Open grant
  • 2010
    Centrosome overduplication contributes to tumorigenesis
    NHMRC Project Grant
    Open grant
  • 2010 - 2015
    NHMRC Research Fellowship: Senior Research Fellowship A
    NHMRC Research Fellowship
    Open grant
  • 2010 - 2012
    Synthetic lethality screen targeting a defective checkpoint in melanoma
    Cancer Council Queensland
    Open grant
  • 2009
    Proteomic studies in cancer, immunology and metabolism research
    UQ Institute Co-Funding
    Open grant
  • 2009 - 2012
    The role of tumour-initiating cells in glioma
    NHMRC Project Grant
    Open grant
  • 2008 - 2009
    Histone deacetylase inhibitors can inhibit tumour growth via induction of an anti-tumour immune response
    Cancer Council Queensland
    Open grant
  • 2008 - 2009
    Is the heterochromatin checkpoint a useful anti-cancer drug target?
    Cancer Council Queensland
    Open grant
  • 2008
    Confocal Microscopy
    UQ Major Equipment and Infrastructure
    Open grant
  • 2007 - 2009
    CDK4 activity in S/G2 phases influences mitotic fidelity
    NHMRC Project Grant
    Open grant
  • 2007 - 2009
    The function of truncated MEK1 in a G2 phase cell cycle delay and in mitosis
    ARC Discovery Projects
    Open grant
  • 2007 - 2009
    Transcriptional complexity of cell cycle regulated genes during cell division and tumorigenesis
    NHMRC Project Grant
    Open grant
  • 2006
    A Facility for High-Throughput, Functional Gene Discovery Using Arrayed Retroviral Expression Cloning
    ARC Linkage Infrastructure, Equipment and Facilities
    Open grant
  • 2006 - 2007
    The molecular basis for the initiation of squamous differentiation
    Queensland Cancer Fund
    Open grant
  • 2005 - 2006
    G2 phase cdk4 activity regulates expression of proteins essential for the fidelity of mitosis: a target for UV-induced p16 expression
    Queensland Cancer Fund
    Open grant
  • 2005 - 2009
    NHMRC SENIOR RESEARCH FELLOWSHIP
    NHMRC Research Fellowship
    Open grant
  • 2004 - 2006
    Function of the unique mitotic form of MEK
    ARC Discovery Projects
    Open grant
  • 2004 - 2006
    Histone Hyperacetylation Affects G2/M Cell Cycle Transition
    NHMRC Project Grant
    Open grant
  • 2004 - 2006
    What Regulates G2 Phase?
    NHMRC Project Grant
    Open grant
  • 2003 - 2004
    Mechanism of UV Induction of the Melanoma Susceptibility Gene Product P16CDKN2A in Skin
    Queensland Cancer Fund
    Open grant
  • 2003
    Zeiss Cell Observer Video Microscopy System
    NHMRC Equipment Grant
    Open grant
  • 2002 - 2003
    Mitotic regulation of the Ras/Raf/MEK/ERK pathway
    Queensland Cancer Fund
    Open grant
  • 2001 - 2002
    NHMRC Equipment Grant 2000
    NHMRC Equipment Grant
    Open grant
  • 2000 - 2001
    Does increased p21 WAF1 expression effect the mechanism of histone deacetylase inhibitor-induced cell death?
    UQ New Staff Research Start-Up Fund
    Open grant

Supervision

Availability

Professor Brian Gabrielli is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Identifying the molecular basis for defective checkpoints in melanoma

  • Targeting defective cell cycle responses to ultraviolet radiation and TopoII inhibitors in melanoma

  • Defining the molecular changes in moles underpinning morphological changes detectable by non-invasive imaging techniques to improve their diagnostic and prognostic ability for early stage melanoma

Supervision history

Current supervision

  • Doctor Philosophy

    AURKi enhances replication stress targeted by CHK1i in p53 and RB defective cells

    Principal Advisor

  • Doctor Philosophy

    Enhancing immune responses to cancer

    Principal Advisor

    Other advisors: Honorary Professor John Hooper, Dr Jazmina Gonzalez Cruz

  • Doctor Philosophy

    Assessment of cell cycle phase-dependent immunogenicity of melanoma treated with the proteasome inhibitor bortezomib

    Associate Advisor

    Other advisors: Professor Nikolas Haass

  • Doctor Philosophy

    Modulating phenotypic melanoma heterogeneity and lymphocyte infiltration to improve both targeted and immune therapy

    Associate Advisor

    Other advisors: Dr Janin Chandra, Professor Nikolas Haass

Completed supervision

Media

Enquiries

Contact Professor Brian Gabrielli directly for media enquiries about:

  • Anti-cancer drugs
  • Cancer - drugs to prevent
  • Cancer - skin
  • Cancer - treatment
  • Cell cycle
  • Drugs - anti-cancer
  • Melanoma
  • Mitosis
  • Radiation - ultraviolet
  • Skin cancer
  • Sun cancer
  • Ultraviolet radiation
  • UV rays

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au